

abandoned, which is a continuation of application Serial No.
07/486,827, filed March 1, 1990, abandoned.--

IN THE CLAIMS

Please amend the following Claims:

Claims 14-17 and 19-23, line 1 of each, change "DNA" to
---cDNA--.

Claim 18, line 1, change "DNA" to --cDNA--, and change
"16" to --17--.

Please add the following new Claims:

EB
--24. The cDNA of Claim 14, obtained by screening a
human cDNA library.

JM
25. The cDNA of Claim 24, wherein said screening
comprises hybridizing a probe having a DNA sequence encoding a
part of porcine brain natriuretic peptide.

JM
26. The cDNA of Claim 25, wherein said probe is obtained
by digesting a complete or incomplete cDNA clone encoding
porcine brain natriuretic peptide with endonucleases XhoI and
RsaI.

27. The cDNA of Claim 26, wherein said probe encodes the
amino acid sequence:

H-Gly Ser Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Ser
Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His-OH.

28. The cDNA of Claim 26, wherein said probe is labelled.

29. The cDNA of Claim 27, wherein said probe consists essentially of the following base sequence:

CGG GCA CCA CGA AGC CCC AAG ATG GTG CAA
GGG TCT GGC TGC TTT GGG AGG AAG ATG GAC CGG ATC AGC
TCC TCC AGT GGC CTG GGC TGC AAA GTG CTG AGG CGG CAT.

EJ
CONT'D
SUB P

30. A method of producing cDNA, comprising:
hybridizing a probe having a DNA sequence encoding a part
of porcine brain natriuretic peptide to a human cDNA library;
selecting a positive clone; and
isolating said cDNA of said positive clone.

31. The method of Claim 30, wherein said cDNA encodes
human brain natriuretic peptide.

32. The method of Claim 31, wherein said probe is
labelled.

33. The method of Claim 31, wherein said probe is
obtained by digesting a complete or incomplete cDNA clone
encoding porcine brain natriuretic peptide with endonucleases
XbaI and RsaI.

C2
cont'd
Sub J

34. The method of Claim 33, wherein said probe encodes the amino acid sequence:

H-Gly Ser Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His-OH.

35. The method of Claim 34, wherein said probe consists essentially of the following base sequence:

CGG GCA CCA CGA AGC CCC AAG ATG GTG CAA
GGG TCT GGC TGC TTT GGG AGG AAG ATG GAC CGG ATC AGC
TCC TCC AGT GGC CTG GGC TGC AAA GTG CTG AGG CGG CAT.--

SUPPORT FOR AMENDMENTS

Support for Claims 24-26 can be found in the present specification on page 4, lines 16-19. Support for Claims 27-29 can be found on page 5, lines 16-24. Support for Claims 30-35 can be found in the support for Claims 24-29, and in the last two lines of page 5 and in the first two line of page 6. Thus, no new matter is introduced by the present Amendment.

Claims 24-35 have been added. Thus, Claims 2-7 and 10-35 are active in the present application.

REMARKS

The present invention concerns a cDNA consisting essentially of, or alternatively, a recombinant DNA sequence comprising a base sequence encoding a polypeptide having one of the following amino acid sequences:

- (1) H-Cys Phe Gly Arg Lys Met Asp Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His-OH;
- (2) H Gly Ser Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His-OH;
- (3) Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His;
- (4) His Pro Leu Gly Ser Pro Gly Ser Ala Ser Asp Leu Glu Thr Ser Gly Leu Gln Glu Gln Arg Asn His Leu Gln Gly Lys Leu Ser Glu Leu Gln Val Glu Gln Thr Ser Leu Glu Pro Leu Gln Glu Ser Pro Arg Pro Thr Gly Val Trp Lys Ser Arg Glu Val Ala Thr Glu Gly Ile Arg Gly His Arg Lys Met Val Leu Tyr Thr Leu Arg Ala Pro Arg Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Ser Ser Ser Gly Leu; and
- (5) Met Asp Pro Gln Thr Ala Pro Ser Arg Ala Leu Leu Leu Leu Leu Phe Leu His Leu Ala Phe Leu Gly Gly Arg Ser His Pro Leu Gly Ser Pro Gly Ser Ala Ser Asp Leu Glu Thr Ser Gly Leu Gln Glu Gln Arg Asn His Leu Gln Gly Lys Leu Ser Glu Leu Gln Val Glu Gln Thr Ser Leu Glu Pro Leu Gln Glu Ser Pro Arg Pro Thr Gly Val Trp Lys Ser Arg Glu Val Ala Thr Glu Gly Ile Arg Gly His Arg Lys Met Val Leu Tyr Thr Leu Arg Ala Pro Arg Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His.

The present invention also concerns a method of producing cDNA, comprising:

hybridizing a probe having a DNA sequence encoding a part of porcine brain natriuretic peptide to a human cDNA library;

selecting a positive clone; and

isolating said cDNA of said positive clone.

As discussed in the Amendment filed July 21, 1993, Seilhamer et al, U.S. Patent No. 5,114,923, appear to teach away from the manner in which the present Inventors proceeded in obtaining the presently claimed DNA sequences. For example, Seilhamer et al repeatedly teach that porcine brain natriuretic peptide (pBNP) DNA would not hybridize to a human DNA library (see column 8, lines 40-51, column 9, lines 32-35 and 45-47, column 22, lines 67-68). Although the human NRP gene disclosed in Figures 5-1 and 5-2 of Seilhamer et al contains introns (additional non-coding sequences present in the coding region), Seilhamer et al equate a human genomic library with a human cDNA library (column 8, line 55 through column 9, line 10), thereby indicating that no unusual problems are expected in screening a genomic library.

Furthermore, Seilhamer et al suggest that no human DNA will successfully hybridize with DNA encoding pBNP (column 22, lines 67-68). Accordingly, viewing the teachings of Seilhamer et al as a whole, one of ordinary skill in the art would expect that using DNA encoding pBNP will not lead to a

successful screening of a positive clone obtained from a human DNA library of any kind.

On the other hand, the present Inventors successfully screened a human cDNA library with a fragment of porcine cDNA encoding pBNP (page 4, line 21, through page 6, line 2, and page 12, line 2 from the bottom, through page 16, line 16 of the present specification). Thus, in view of the failure of Seilhamer et al to hybridize DNA encoding pBNP to human DNA, the success of the present Inventors to obtain DNA encoding human BNP is surprising and unexpected.

The rejection of Claims 2-7 and 10-23 under 35 U.S.C. 103 as being unpatentable over Maekawa et al in view of Maniatis, Sudoh et al, (R) and Sudoh et al (T), Oikawa et al and Vlasuk et al is respectfully traversed.

Maekawa et al disclose cloning and sequence analysis of cDNA encoding a precursor for porcine brain natriuretic peptide (pBNP). Sudoh et al (R) disclose the sequences of porcine BNP and human α -ANP (atrial natriuretic peptide). Sudoh et al (T) disclose a 32-amino acid-long brain natriuretic peptide identified in porcine brain. Oikawa et al disclose the structure of dog and rabbit precursors of atrial natriuretic peptides deduced from nucleotide sequences of cloned cDNA. Vlasuk et al disclose the structure and analysis of the bovine atrial natriuretic peptide precursor gene.

Maniatis et al teach the expression of eucaryotic genes, vectors that express fused and unfused eucaryotic proteins, and synthetic oligodeoxynucleotides useful for hybridizing to

(and screening) mRNA. The method of screening mRNA disclosed by Maniatis et al is essentially the method disclosed by Suggs et al, cited against the present invention by the Examiner in parent application Serial No. 07/486,827, and withdrawn by the Examiner in the present application. Similar to the teachings of Suggs et al, one must scan the known protein sequence for areas rich in amino acids specified by one or two codons (page 226, lines 3-6 from the bottom). The oligonucleotides of Maniatis et al, similar to those of Suggs et al, form hybrids only with those species of mRNA to which they are exactly complementary (page 227, lines 4-7).

Therefore, although Maniatis et al suggest that their oligodeoxynucleotides can be used as probes to screen cDNA libraries, the teachings of Maniatis et al fail to cure the deficiencies of the remaining of the cited references. Prior to the present invention, the amino acid sequence of human BNP was not known. However, the method of Maniatis et al requires that the amino acid sequence be known. Further, without the absolute assurance that there will be at least one probe which is exactly complementary to the target sequence provided by knowledge of the amino acid sequence, success cannot be achieved. One cannot have a reasonable expectation of success using the method of Maniatis et al when the amino acid sequence encoded by the target sequence is not known.

However, assuming arguendo that it would have been obvious for one of ordinary skill in the art to use the DNA sequence disclosed by Maekawa et al, or an effective portion

thereof (as taught by Seilhamer et al [col. 8, lines 40-54]), as a probe to screen for the human BNP gene, the clear failure of Seilhamer et al to successfully achieve this result attests to the nonobviousness of the present DNA. Interestingly, as discussed above, Seilhamer et al equate a genomic library with a cDNA library, thereby indicating that no unusual problems are expected in screening a genomic library. Even more interesting, the temperature conditions used by Seilhamer et al were less stringent (37-42°C; col. 9, lines 6-10 and 38-42) than those used to obtain the present DNA sequences (60°C; page 14, line 19 of the present specification).

The teachings of Seilhamer et al are clearly more relevant to the presently claimed invention than the combined teachings of the cited references, which neither disclose nor suggest screening a human DNA library with cDNA encoding porcine BNP. Therefore, the combined teachings of the cited references do not overcome the evidence of the difficulties encountered in obtaining the present invention as described by Seilhamer et al. Therefore, this ground of rejection is unsustainable, and should be withdrawn.

A leap of faith appears to have been made in the assertions on page 5, lines 9-25 of the Official Action of October 6, 1993. Assuming for the sake of argument that the analyses of the cited references set forth in the Official Action are correct, teachings that (1) porcine BNP and human ANP are homologous and that (2) cDNA's of ANP can be used to isolate the cDNA's of other species does not lead one to the

expectation that a porcine BNP DNA probe will lead to isolation of human BNP DNA. The Examiner has apparently assumed either that (A) human ANP is the same as human BNP, or that (B) cDNA's of ANP are the same as cDNA's of BNP. Unless the Examiner can show that (i) porcine BNP and human BNP are homologous, or that (ii) porcine BNP cDNA can be used to isolate the human BNP cDNA, a leap of faith which runs counter to the evidence on the record must be made.

Therefore, this ground of rejection is unsustainable, and should be withdrawn.

Accordingly, the present application is in condition for allowance. Early notice to that effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Andrew D. Fortney, Ph.D.
Registration No. 34,600

Crystal Square Five - Fourth Floor
1755 South Jefferson Davis Highway
Arlington, VA 22202
(703) 413-3000
ADF